<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">brhejo</journal-id><journal-title-group><journal-title xml:lang="en">The BRICS Health Journal</journal-title><trans-title-group xml:lang="ru"><trans-title>The BRICS Health Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">3034-4700</issn><issn pub-type="epub">3034-4719</issn><publisher><publisher-name>Sechenov University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47093/3034-4700.2025.2.4.30-44</article-id><article-id custom-type="elpub" pub-id-type="custom">brhejo-69</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>From global experience to the Russian future: strategic vectors for the development of pediatric hematology and oncology</article-title><trans-title-group xml:lang="ru"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4451-3233</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Grachev</surname><given-names>Nikolay S.</given-names></name></name-alternatives><bio xml:lang="en"><p>Nikolay S. Grachev, MD, DSc, Professor, General director</p><p>1, Samory Mashela str., Moscow, 117198</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8385-4356</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Blinov</surname><given-names>Dmitrii S.</given-names></name></name-alternatives><bio xml:lang="en"><p>Dmitrii S. Blinov, MD, DSc, Scientific Board Secretary</p><p>1, Samory Mashela str., Moscow, 117198</p></bio><email xlink:type="simple">dmitriy.blinov@dgoi.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1643-5960</contrib-id><name-alternatives><name name-style="western" xml:lang="en"><surname>Rumyantsev</surname><given-names>Aleksander G.</given-names></name></name-alternatives><bio xml:lang="en"><p>Aleksander G. Rumyantsev, MD, DSc, Professor, Academician of Russian Academy of Sciences,President</p><p>1, Samory Mashela str., Moscow, 117198</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="en" id="aff-1"><institution>Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>26</day><month>04</month><year>2026</year></pub-date><volume>2</volume><issue>4</issue><fpage>30</fpage><lpage>44</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Grachev N.S., Blinov D.S., Rumyantsev A.G., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Grachev N.S., Blinov D.S., Rumyantsev A.G.</copyright-holder><copyright-holder xml:lang="en">Grachev N.S., Blinov D.S., Rumyantsev A.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.bricshealthjournal.com/jour/article/view/69">https://www.bricshealthjournal.com/jour/article/view/69</self-uri><abstract><p>The article focuses on the analysis of current issues and challenges facing pediatric oncology and hematology. Data on cancer incidence in children at the level of economic development of the state, relative to the healthcare model are provided. The main characteristics of oncological care systems in economically developed countries and in developing countries around the world are identified, and the features of the Russian model are emphasized. Particular attention is paid to recent technologies and development vectors of molecular-targeted, cell therapy, precision surgery. The role of information technology and digital transformations in increasing the efficiency of healthcare models for providing oncological care to children in Russia is shown. National and foreign experience convincingly proves that a breakthrough in pediatric oncology is possible only with a systematic approach combining scientific innovations with access to medical care. Russia, being at a unique stage of development, demonstrates both significant successes in the field of high technologies and persistent structural problems. Thus, the key vector of development is not only the introduction of individual innovations but also solving fundamental tasks of standardization, overcoming regional inequality, and developing personnel potential, which will allow fully realizing the accumulated scientific and clinical potential.</p></abstract><kwd-group xml:lang="en"><kwd>pediatric oncology</kwd><kwd>oncohematology</kwd><kwd>healthcare system</kwd><kwd>model challenges</kwd><kwd>medical technologies</kwd><kwd>molecular and cellular treatment methods</kwd><kwd>oncosurgery</kwd><kwd>prospects</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ward ZJ, Yeh JM, Bhakta N, Frazier AL, Girardi F, Atun R. Global childhood cancer survival estimates and priority-setting: a simulation-based analysis. Lancet Oncol. 2019;20(7):972–983. doi:10.1016/S1470-2045(19)30273-6</mixed-citation><mixed-citation xml:lang="en">Ward ZJ, Yeh JM, Bhakta N, Frazier AL, Girardi F, Atun R. Global childhood cancer survival estimates and priority-setting: a simulation-based analysis. Lancet Oncol. 2019;20(7):972–983. doi:10.1016/S1470-2045(19)30273-6</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bhakta N, Force LM, Allemani C, et al. Childhood cancer burden: a review of global estimates. Lancet Oncol. 2019;20(1):e42–e53. doi:10.1016/S1470-2045(18)30761-7</mixed-citation><mixed-citation xml:lang="en">Bhakta N, Force LM, Allemani C, et al. Childhood cancer burden: a review of global estimates. Lancet Oncol. 2019;20(1):e42–e53. doi:10.1016/S1470-2045(18)30761-7</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Atun R, Bhakta N, Denburg A, et al. Sustainable care for children with cancer: a Lancet Oncology Commission. Lancet Oncol. 2020;21(4):e185–e224. doi:10.1016/ S1470-2045(20)30022-X</mixed-citation><mixed-citation xml:lang="en">Atun R, Bhakta N, Denburg A, et al. Sustainable care for children with cancer: a Lancet Oncology Commission. Lancet Oncol. 2020;21(4):e185–e224. doi:10.1016/ S1470-2045(20)30022-X</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Demina I, Dagestani A, Borkovskaia A, et al. Immunophenotypic but not genetic changes reclassify the majority of relapsed/refractory pediatric cases of early T-cell precursor acute lymphoblastic leukemia. International Journal of Molecular Sciences. 2024;25(11):5610. doi:10.3390/ijms25115610</mixed-citation><mixed-citation xml:lang="en">Demina I, Dagestani A, Borkovskaia A, et al. Immunophenotypic but not genetic changes reclassify the majority of relapsed/refractory pediatric cases of early T-cell precursor acute lymphoblastic leukemia. International Journal of Molecular Sciences. 2024;25(11):5610. doi:10.3390/ijms25115610</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33(27):2938–2948. doi:10.1200/JCO.2014.59.1636</mixed-citation><mixed-citation xml:lang="en">Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33(27):2938–2948. doi:10.1200/JCO.2014.59.1636</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Pshonkin AV, Rumyantseva YuV, Litvinov DV, et al. Treatment of acute lymphoblastic leukemia in adolescents and young adults: the experience of the Moscow–Berlin. Russian Journal of Pediatric Hematology and Oncology. 2016;3(1):35–43. (In Russian). doi:10.17650/2311-1267-2016-3-1-35-43</mixed-citation><mixed-citation xml:lang="en">Pshonkin AV, Rumyantseva YuV, Litvinov DV, et al. Treatment of acute lymphoblastic leukemia in adolescents and young adults: the experience of the Moscow–Berlin. Russian Journal of Pediatric Hematology and Oncology. 2016;3(1):35–43. (In Russian). doi:10.17650/2311-1267-2016-3-1-35-43</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Armstrong GT, Chen Y, Yasui Y, et al. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med. 2016;374(9):833–842. doi:10.1056/NEJMoa1510795</mixed-citation><mixed-citation xml:lang="en">Armstrong GT, Chen Y, Yasui Y, et al. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med. 2016;374(9):833–842. doi:10.1056/NEJMoa1510795</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Magrath I, Steliarova-Foucher E, Epelman S, et al. Paediatric cancer in low-income and middle-income countries. Lancet Oncol. 2013;14(3):e104–e116. doi:10.1016/S1470-2045(13)70008-1</mixed-citation><mixed-citation xml:lang="en">Magrath I, Steliarova-Foucher E, Epelman S, et al. Paediatric cancer in low-income and middle-income countries. Lancet Oncol. 2013;14(3):e104–e116. doi:10.1016/S1470-2045(13)70008-1</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Howard SC, Zaidi A, Cao X, et al. The My Child Matters programme: effect of public-private partnerships on paediatric cancer care in low-income and middle-income countries. Lancet Oncol. 2018;19(5):e252-e266. doi:10.1016/S1470-2045(18)30123-2.</mixed-citation><mixed-citation xml:lang="en">Howard SC, Zaidi A, Cao X, et al. The My Child Matters programme: effect of public-private partnerships on paediatric cancer care in low-income and middle-income countries. Lancet Oncol. 2018;19(5):e252-e266. doi:10.1016/S1470-2045(18)30123-2.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Yeh JM, Ward ZJ, Chaudhry A, et al. Life expectancy of adult survivors of childhood cancer over 3 decades. JAMA Oncol. 2020;6(3):350-357. doi:10.1001/jamaoncol.2019.5582</mixed-citation><mixed-citation xml:lang="en">Yeh JM, Ward ZJ, Chaudhry A, et al. Life expectancy of adult survivors of childhood cancer over 3 decades. JAMA Oncol. 2020;6(3):350-357. doi:10.1001/jamaoncol.2019.5582</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Shishkin S, Sheiman I, Vlassov V, Potapchik E, Sazhina S. Structural changes in the Russian health care system: do they match European trends? Health Econ Rev. 2022;12(1):29. doi:10.1186/s13561-022-00373-z</mixed-citation><mixed-citation xml:lang="en">Shishkin S, Sheiman I, Vlassov V, Potapchik E, Sazhina S. Structural changes in the Russian health care system: do they match European trends? Health Econ Rev. 2022;12(1):29. doi:10.1186/s13561-022-00373-z</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lozovaya VV, Gusarova OA, Matinyan NV, et al. Percutaneous endoscopic gastrostomy as a minimally invasive and most effective method of longterm nutritional support in children with cancer (single-center study). Russian Journal of Pediatric Hematology and Oncology. 2024;11(1):27–35. (In Russian). doi:10.21682/2311-1267-2024-11-1-27-35</mixed-citation><mixed-citation xml:lang="en">Lozovaya VV, Gusarova OA, Matinyan NV, et al. Percutaneous endoscopic gastrostomy as a minimally invasive and most effective method of longterm nutritional support in children with cancer (single-center study). Russian Journal of Pediatric Hematology and Oncology. 2024;11(1):27–35. (In Russian). doi:10.21682/2311-1267-2024-11-1-27-35</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Polyakov VG, Baibarina EN, Chumakova OV, Susuleva NA, Rykov MYu. Medical care for children with cancer in the Russian Federation. Onkopediatria. 2015;2(3):177–187. (In Russian). doi:10.15690/onco.v2.i3.1395</mixed-citation><mixed-citation xml:lang="en">Polyakov VG, Baibarina EN, Chumakova OV, Susuleva NA, Rykov MYu. Medical care for children with cancer in the Russian Federation. Onkopediatria. 2015;2(3):177–187. (In Russian). doi:10.15690/onco.v2.i3.1395</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kirgizov KI, Kogan SA, Erdomaeva YaA, et al. The development of pediatric oncologyhematology in the Russian Federation: the experience of collaboration between the National Society of Pediatric Hematologists and Oncologists and the National Medical Research Center. Russian Journal of Pediatric Hematology and Oncology. 2019;6(3):12–25. (In Russian). doi:10.21682/2311-1267-2019-6-3-12-25</mixed-citation><mixed-citation xml:lang="en">Kirgizov KI, Kogan SA, Erdomaeva YaA, et al. The development of pediatric oncologyhematology in the Russian Federation: the experience of collaboration between the National Society of Pediatric Hematologists and Oncologists and the National Medical Research Center. Russian Journal of Pediatric Hematology and Oncology. 2019;6(3):12–25. (In Russian). doi:10.21682/2311-1267-2019-6-3-12-25</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Smirnova LA, Mitrofanova AM, Merkulov NN, et al. Renal cell carcinoma in children: the results of retrospective analysis. Russian Journal of Pediatric Hematology and Oncology. 2023;10(2):11–27. (In Russian). doi:10.21682/2311-1267-2023-10-2-11-27</mixed-citation><mixed-citation xml:lang="en">Smirnova LA, Mitrofanova AM, Merkulov NN, et al. Renal cell carcinoma in children: the results of retrospective analysis. Russian Journal of Pediatric Hematology and Oncology. 2023;10(2):11–27. (In Russian). doi:10.21682/2311-1267-2023-10-2-11-27</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Aksenova IA, Popova NV, Starinsky VV, et al. Analysis of the epidemiology of malignant neoplasms among the child population in the Russian Federation. Problems in Oncology. 2025;71(1). (In Russian). doi:10.37469/0507-3758-2025-71-1-OF-2169</mixed-citation><mixed-citation xml:lang="en">Aksenova IA, Popova NV, Starinsky VV, et al. Analysis of the epidemiology of malignant neoplasms among the child population in the Russian Federation. Problems in Oncology. 2025;71(1). (In Russian). doi:10.37469/0507-3758-2025-71-1-OF-2169</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Arakelyan SK, Blagov SL, Kovrygin SI, et al. Daratumumab in the treatment of pure red cell aplasia after pediatric allogeneic stem cell transplantation. Pediatric Hematology/Oncology and Immunopathology. 2023;22(2):104–112. doi:10.24287/1726-1708-2023-22-2-104-112</mixed-citation><mixed-citation xml:lang="en">Arakelyan SK, Blagov SL, Kovrygin SI, et al. Daratumumab in the treatment of pure red cell aplasia after pediatric allogeneic stem cell transplantation. Pediatric Hematology/Oncology and Immunopathology. 2023;22(2):104–112. doi:10.24287/1726-1708-2023-22-2-104-112</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Merabishvili VM, Kylyova SA. The state of oncology care in Russia: adolescents’ epidemiology and survival (15–17 years). Modern diagnostic and treatment options. Populated study at the federal district level. Russian Journal of Pediatric Hematology and Oncology. 2025;12(2):13–19. (In Russian). doi:10.21682/2311-1267-2025-12-2-13-19</mixed-citation><mixed-citation xml:lang="en">Merabishvili VM, Kylyova SA. The state of oncology care in Russia: adolescents’ epidemiology and survival (15–17 years). Modern diagnostic and treatment options. Populated study at the federal district level. Russian Journal of Pediatric Hematology and Oncology. 2025;12(2):13–19. (In Russian). doi:10.21682/2311-1267-2025-12-2-13-19</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Valiev TT, Levashov AS, Batmanova NA, et al. Targeted therapy in pediatric malignancies treatment: Pediatric Oncology and Haematology Research Institute experience. Journal of Modern Oncology. 2017;19(2):54–60.</mixed-citation><mixed-citation xml:lang="en">Valiev TT, Levashov AS, Batmanova NA, et al. Targeted therapy in pediatric malignancies treatment: Pediatric Oncology and Haematology Research Institute experience. Journal of Modern Oncology. 2017;19(2):54–60.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tsaplina NS, Kozlov AV, Valiev TT, et al. Treatment of children with relapsed and refractory classical Hodgkin’s lymphoma: the experience of two centers. Russian Journal of Pediatric Hematology and Oncology. 2024;11(3):22–29. (In Russian). doi:10.21682/2311-1267-2024-11-3-22-29</mixed-citation><mixed-citation xml:lang="en">Tsaplina NS, Kozlov AV, Valiev TT, et al. Treatment of children with relapsed and refractory classical Hodgkin’s lymphoma: the experience of two centers. Russian Journal of Pediatric Hematology and Oncology. 2024;11(3):22–29. (In Russian). doi:10.21682/2311-1267-2024-11-3-22-29</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Romantsova OM, Prishchep PL, Khairullova VV, et al. System for early prediction of progression of Ewing’s sarcoma in children. Russian Journal of Pediatric Hematology and Oncology. 2024;11(4):51–59. (In Russian). doi:10.21682/2311-1267-2024-11-4-51-59</mixed-citation><mixed-citation xml:lang="en">Romantsova OM, Prishchep PL, Khairullova VV, et al. System for early prediction of progression of Ewing’s sarcoma in children. Russian Journal of Pediatric Hematology and Oncology. 2024;11(4):51–59. (In Russian). doi:10.21682/2311-1267-2024-11-4-51-59</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Dunaykina MA, Shelikhova LN, Shekhovtsova ZB, et al. The safety and effectiveness of donor memory T lymphocyte infusions after hematopoietic stem cell transplantation with ab T cell depletion platform in children with acute leukemia. Pediatric Hematology/Oncology and Immunopathology. 2021;20(2):12–28. doi:10.24287/1726-1708-2021-20-2-12-28</mixed-citation><mixed-citation xml:lang="en">Dunaykina MA, Shelikhova LN, Shekhovtsova ZB, et al. The safety and effectiveness of donor memory T lymphocyte infusions after hematopoietic stem cell transplantation with ab T cell depletion platform in children with acute leukemia. Pediatric Hematology/Oncology and Immunopathology. 2021;20(2):12–28. doi:10.24287/1726-1708-2021-20-2-12-28</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Balashov DN, Laberko AL, Skvortsova YV, et al. The use of thiotepa in reduced toxicity conditioning regimens before hematopoietic stem cell transplantation in primary immunodeficiencies. Pediatric Hematology/Oncology and Immunopathology. 2024;23(2):71–77. doi:10.24287/1726-1708-2024-23-2-71-77</mixed-citation><mixed-citation xml:lang="en">Balashov DN, Laberko AL, Skvortsova YV, et al. The use of thiotepa in reduced toxicity conditioning regimens before hematopoietic stem cell transplantation in primary immunodeficiencies. Pediatric Hematology/Oncology and Immunopathology. 2024;23(2):71–77. doi:10.24287/1726-1708-2024-23-2-71-77</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Kazantsev IV, Gevorgyan AG, Yukhta TV, et al. The complex intensive therapy regimen as curative therapy in patients with primary-resistant and relapsed neuroblastoma: R.M. Gorbacheva Memorial Institute for Children Oncology, Hematology and Transplantation experience. Pediatric Hematology/Oncology and Immunopathology. 2020:19(2):129–140. doi:10.24287/1726-1708-2020-19-2-129-140</mixed-citation><mixed-citation xml:lang="en">Kazantsev IV, Gevorgyan AG, Yukhta TV, et al. The complex intensive therapy regimen as curative therapy in patients with primary-resistant and relapsed neuroblastoma: R.M. Gorbacheva Memorial Institute for Children Oncology, Hematology and Transplantation experience. Pediatric Hematology/Oncology and Immunopathology. 2020:19(2):129–140. doi:10.24287/1726-1708-2020-19-2-129-140</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Smirnova DS, Kirgizov KI, Kazantsev IV, et al. Tandem hematopoietic stem cell transplantation in children with solid tumors in the Russian Federation: results of a retrospective multicenter study. Russian Journal of Pediatric Hematology and Oncology. 2025;12(2):63–72. (In Russian). doi:10.21682/2311-1267-2025-12-2-63-72</mixed-citation><mixed-citation xml:lang="en">Smirnova DS, Kirgizov KI, Kazantsev IV, et al. Tandem hematopoietic stem cell transplantation in children with solid tumors in the Russian Federation: results of a retrospective multicenter study. Russian Journal of Pediatric Hematology and Oncology. 2025;12(2):63–72. (In Russian). doi:10.21682/2311-1267-2025-12-2-63-72</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Resolution of the Council of Experts “Issues of using CAR-T drugs in the treatment of B-cell acute lymphoblastic leukemia”. Russian Journal of Pediatric Hematology and Oncology. 2024;11(3):87–91. (In Russian). doi:10.21682/2311-1267-2024-11-3-87-91</mixed-citation><mixed-citation xml:lang="en">Resolution of the Council of Experts “Issues of using CAR-T drugs in the treatment of B-cell acute lymphoblastic leukemia”. Russian Journal of Pediatric Hematology and Oncology. 2024;11(3):87–91. (In Russian). doi:10.21682/2311-1267-2024-11-3-87-91</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Popova MО, Markelov VV. CAR-T: from bench to bedside. Oncohematology. 2024;19(3):185–198. (In Russian). doi:10.17650/1818-8346-2024-19-3-185-198.</mixed-citation><mixed-citation xml:lang="en">Popova MО, Markelov VV. CAR-T: from bench to bedside. Oncohematology. 2024;19(3):185–198. (In Russian). doi:10.17650/1818-8346-2024-19-3-185-198.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Ershov AV, Demyanov GV, Nasrullaeva DA, et al. The latest trends in improving CAR-T cell therapy: from leukemia to solid malignant tumors. Russian Journal of Pediatric Hematology and Oncology. 2021;8(2):84–95. (In Russian). doi:10.21682/2311-1267-2021-8-2-84-95</mixed-citation><mixed-citation xml:lang="en">Ershov AV, Demyanov GV, Nasrullaeva DA, et al. The latest trends in improving CAR-T cell therapy: from leukemia to solid malignant tumors. Russian Journal of Pediatric Hematology and Oncology. 2021;8(2):84–95. (In Russian). doi:10.21682/2311-1267-2021-8-2-84-95</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Akhaladze DG, Tuponogov SN, Chvanova AV, et al. A rare experience of treating calcifying nested stromal tumor of the liver in children. Pediatric Hematology/ Oncology and Immunopathology. 2022;21(4):111–117. doi:10.24287/1726-1708-2022-21-4-111-117</mixed-citation><mixed-citation xml:lang="en">Akhaladze DG, Tuponogov SN, Chvanova AV, et al. A rare experience of treating calcifying nested stromal tumor of the liver in children. Pediatric Hematology/ Oncology and Immunopathology. 2022;21(4):111–117. doi:10.24287/1726-1708-2022-21-4-111-117</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Grachev NS, Starokorova KD, Markov NM, et al. A clinical case of reconstruction of the lower third of the face in an eight-year-old patient after successful complex treatment for an extrarenal rhabdoid tumor of the soft tissues of the chin. Russian Journal of Pediatric Hematology and Oncology. 2024;11(2):85–89. (In Russian). doi:10.21682/2311-1267-2024-11-2-85-89</mixed-citation><mixed-citation xml:lang="en">Grachev NS, Starokorova KD, Markov NM, et al. A clinical case of reconstruction of the lower third of the face in an eight-year-old patient after successful complex treatment for an extrarenal rhabdoid tumor of the soft tissues of the chin. Russian Journal of Pediatric Hematology and Oncology. 2024;11(2):85–89. (In Russian). doi:10.21682/2311-1267-2024-11-2-85-89</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Nikolskaya NS, Khain AE, Evdokimova MA, Shelikhova LN, Skvortsova YV. Quality of life and subjective well-being of children and caregivers at different stages of allogeneic hematopoietic stem cell transplantation. Pediatric Hematology/ Oncology and Immunopathology. 2024:23(3):116–122. doi:10.24287/1726-1708-2024-23-3-116-122</mixed-citation><mixed-citation xml:lang="en">Nikolskaya NS, Khain AE, Evdokimova MA, Shelikhova LN, Skvortsova YV. Quality of life and subjective well-being of children and caregivers at different stages of allogeneic hematopoietic stem cell transplantation. Pediatric Hematology/ Oncology and Immunopathology. 2024:23(3):116–122. doi:10.24287/1726-1708-2024-23-3-116-122</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Morozov SP, Vladzimirskyy AV, Ledikhova NV, et al. Moscow experiment on computer vision in radiology: involvement and participation of radiologists. Medical Doctor and Information Technologies. 2020;(4):14–23.</mixed-citation><mixed-citation xml:lang="en">Morozov SP, Vladzimirskyy AV, Ledikhova NV, et al. Moscow experiment on computer vision in radiology: involvement and participation of radiologists. Medical Doctor and Information Technologies. 2020;(4):14–23.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
